Beta-adrenergic signaling: double edged sword of myocardial repair

β-肾上腺素能信号传导:心肌修复的双刃剑

基本信息

  • 批准号:
    8431986
  • 负责人:
  • 金额:
    $ 37.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-02-15 至 2018-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The myocardium possesses an inherent capacity for cellular replacement, yet this reparative process is inadequate to cope with acute injury or chronic stress. Discovery of cardiac progenitor cells (CPCs) has established the heart as a dynamic organ with CPCs emerging as an efficacious choice for cardiomyoplastic repair. Myocardial structure and function is significantly improved by regenerative interventional approaches, but functional restoration of myocardial repair will inevitably require deciphering the molecular signaling that impairs cellular replacement and healing. The overarching premises of this proposal is that myocardial reparative mechanisms become compromised by pathologic stimuli leading to a downward spiral of cardiac insufficiency linked to inadequate cellular replacement. Specifically, this proposal delineates the relationship between ?-adrenergic receptor (?-AR) signaling and CPC-mediated reparative processes. ?-AR signaling regulates cardiac contractility and adaptation to physiological and pathological stress, but the impact upon maintenance of CPC function in response to acute injury and chronic stress has never been studied. Preliminary results indicate differential expression of ?1- versus ?2-ARs in uncommitted versus early cardiogenic CPCs, and this shift in receptor profile exerts profoundly divergent effects upon survival and proliferation. Therefore, short-term goals are to understand the consequences of ?-AR signaling for CPC function in the myocardium and extend these findings to develop therapeutic interventional strategies to empower CPC-mediated regeneration through manipulation of adrenergic drive. Translational potential of these findings will be explored using clinically relevant pharmacologic agents as well as a lentiviral vector engineered to express ?ARK-ct to improve survival, proliferation engraftment and commitment of CPCs in failing hearts. Specific aims are: 1) ?2-adrenergic system regulates cardiac progenitor cell function, 2) CPC survival is antagonized by ?1-adrenergic receptor acquired during cardiac commitment, 3) CPC mediated myocardial repair is restored by ?-blockade in failing hearts, and 4) Regenerative potential of human CPCs is augmented by ?ARK-ct overexpression. The significance of the study is to understand the underlying molecular signaling affecting endogenous myocardial repair capability. Innovation rests with the novel intersection of adrenergic drive and wound healing in the myocardium, examined with a cutting edge combination of cellular, molecular, and animal models to cover the spectrum of basic studies that include human CPCs derived from heart failure patients: the exact target population that would benefit most from the successful completion of the proposed studies. The long term goal is to redefine perceptions of ?-adrenergic drive as "pathologic" and reveal the potential of leveraging adrenergic drive to enhance myocardial regeneration while concurrently preserving mature myocardium.
描述(由申请人提供):心肌具有固有的细胞置换能力,但是这种修复过程不足以应对急性损伤或慢性应激。心脏祖细胞(CPC)的发现已确立了心脏作为动态器官,CPC出现了,作为心肌塑性修复的有效选择。心肌结构和功能通过再生介入方法可显着改善,但是心肌修复的功能恢复将不可避免地需要破译 损害细胞置换和愈合的分子信号传导。该提案的总体前提是,心肌修复机制受到病理刺激的损害,导致与细胞替代不足有关的心脏不足螺旋式下降。具体而言,该提案描述了肾上腺素能受体(?-AR)信号传导与CPC介导的修复过程之间的关系。 ? - AR信号传导调节心脏收缩性并适应生理和病理压力,但是从未研究过对CPC功能维持对CPC功能维持的影响。初步结果表明,在不合同的和早期心源性CPC中,1- 1-ARS的差异表达,受体谱的这种转移对生存和增殖产生了明显不同的影响。因此,短期目标是了解心肌中CPC功能的影响的后果,并将这些发现扩展到制定治疗性介入策略,以通过操纵肾上腺素驱动来增强CPC介导的再生能力。这些发现的转化潜力将使用临床上相关的药理学剂以及设计用于表达ARK-CT的慢病毒载体,以提高生存率,增殖植入和CPC的承诺。 Specific aims are: 1) ?2-adrenergic system regulates cardiac progenitor cell function, 2) CPC survival is antagonized by ?1-adrenergic receptor acquired during cardiac commitment, 3) CPC mediated myocardial repair is restored by ?-blockade in failing hearts, and 4) Regenerative potential of human CPCs is augmented by ?ARK-ct overexpression.该研究的重要性是了解影响内源性心肌修复能力的潜在分子信号。创新取决于肾上腺素能驱动和心肌中伤口愈合的新型交集,并通过细胞,分子和动物模型的尖端组合进行了检查,以涵盖包括心力衰竭患者的人类CPC的频谱:从心力衰竭患者中得出的基本研究:确切的目标人群将从提出的研究成功完成中受益最大的目标人群。长期的目标是重新定义对肾上腺素能驱动为“病理学”的看法,并揭示利用肾上腺素能驱动以增强心肌再生的潜力,同时同时保留成熟的心肌。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARK ALAN SUSSMAN其他文献

MARK ALAN SUSSMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARK ALAN SUSSMAN', 18)}}的其他基金

Next Generation Regenerative Therapy with Pim-1 Enhanced Cardiac Progenitor Cells
使用 Pim-1 增强型心脏祖细胞的下一代再生疗法
  • 批准号:
    9352458
  • 财政年份:
    2017
  • 资助金额:
    $ 37.38万
  • 项目类别:
Enhanced Myocardial Repair with CardioClusters and CardioChimeras
利用 CardioClusters 和 CardioChimeras 增强心肌修复
  • 批准号:
    9266810
  • 财政年份:
    2014
  • 资助金额:
    $ 37.38万
  • 项目类别:
Enhanced Myocardial Repair with CardioClusters and CardioChimeras
利用 CardioClusters 和 CardioChimeras 增强心肌修复
  • 批准号:
    8675146
  • 财政年份:
    2014
  • 资助金额:
    $ 37.38万
  • 项目类别:
Enhanced Myocardial Repair with CardioClusters and CardioChimeras
利用 CardioClusters 和 CardioChimeras 增强心肌修复
  • 批准号:
    9041013
  • 财政年份:
    2014
  • 资助金额:
    $ 37.38万
  • 项目类别:
Beta-adrenergic signaling: double edged sword of myocardial repair
β-肾上腺素能信号传导:心肌修复的双刃剑
  • 批准号:
    8790766
  • 财政年份:
    2013
  • 资助金额:
    $ 37.38万
  • 项目类别:
Cardioprotection by optimizing mTOR activity
通过优化 mTOR 活性来保护心脏
  • 批准号:
    8446101
  • 财政年份:
    2013
  • 资助金额:
    $ 37.38万
  • 项目类别:
Cardioprotection by optimizing mTOR activity
通过优化 mTOR 活性来保护心脏
  • 批准号:
    8792404
  • 财政年份:
    2013
  • 资助金额:
    $ 37.38万
  • 项目类别:
Beta-adrenergic signaling: double edged sword of myocardial repair
β-肾上腺素能信号传导:心肌修复的双刃剑
  • 批准号:
    8996702
  • 财政年份:
    2013
  • 资助金额:
    $ 37.38万
  • 项目类别:
Cardioprotection by optimizing mTOR activity
通过优化 mTOR 活性来保护心脏
  • 批准号:
    8620713
  • 财政年份:
    2013
  • 资助金额:
    $ 37.38万
  • 项目类别:
Beta-adrenergic signaling: double edged sword of myocardial repair
β-肾上腺素能信号传导:心肌修复的双刃剑
  • 批准号:
    8620715
  • 财政年份:
    2013
  • 资助金额:
    $ 37.38万
  • 项目类别:

相似国自然基金

阿魏酸基天然抗氧化抗炎纳米药物用于急性肾损伤诊疗一体化研究
  • 批准号:
    82302281
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
SGO2/MAD2互作调控肝祖细胞的细胞周期再进入影响急性肝衰竭肝再生的机制研究
  • 批准号:
    82300697
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
基于hemin-MOFs的急性心肌梗塞标志物负背景光电化学-比色双模分析
  • 批准号:
    22304039
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
RNA甲基转移酶NSUN2介导SCD1 mRNA m5C修饰调控急性髓系白血病细胞铁死亡的机制研究
  • 批准号:
    82300173
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
基于IRF5/MYD88信号通路调控巨噬细胞M1极化探讨针刀刺营治疗急性扁桃体炎的机制研究
  • 批准号:
    82360957
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    地区科学基金项目

相似海外基金

Rhinovirus, airway smooth muscle, and mechanisms of irreversible airflow obstruction
鼻病毒、气道平滑肌和不可逆气流阻塞机制
  • 批准号:
    10735460
  • 财政年份:
    2023
  • 资助金额:
    $ 37.38万
  • 项目类别:
S-nitrosylation signaling in asthma
哮喘中的 S-亚硝基化信号传导
  • 批准号:
    10662243
  • 财政年份:
    2021
  • 资助金额:
    $ 37.38万
  • 项目类别:
S-nitrosylation signaling in asthma
哮喘中的 S-亚硝基化信号传导
  • 批准号:
    10457996
  • 财政年份:
    2021
  • 资助金额:
    $ 37.38万
  • 项目类别:
S-nitrosylation signaling in asthma
哮喘中的 S-亚硝基化信号传导
  • 批准号:
    10269972
  • 财政年份:
    2021
  • 资助金额:
    $ 37.38万
  • 项目类别:
Role of S-Nitrosylation on Beta-Adrenergic Signaling in Cardiac Injury and Repair
S-亚硝基化对 β-肾上腺素能信号传导在心脏损伤和修复中的作用
  • 批准号:
    10370376
  • 财政年份:
    2021
  • 资助金额:
    $ 37.38万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了